Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. (ACRS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
acrs · stock forecast · 16 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 16 Wall Street analysts in the past 3 months
Buy
16 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$12.00
Consensus
$10.60
+143.1% upside
Low
$10.00
Median: $10 · Last Close: $4.36
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$10.60
143.1% upside
High Target
$12
175.2%
Low Target
$10
129.4%
Current Price
$4.36
as of today
Based on analyst price targets, the ACRS stock price prediction for the next 12 months ranges from $10 to $12. The consensus ACRS price forecast of $10.60 implies 143.1% upside from the current price of $4.36.
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $4.28 | ↓ 1.78% |
1-day model range: $4.25–$4.31. Peak: $4.31 (-1.78%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ACRS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-05 | Piper Sandler | Maintains | Overweight→Overweight |
| 2026-04-29 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-31 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-01-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-01-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-06-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-09 | Scotiabank | Maintains | Sector Outperform→Sector Outperform |
Wall Street analysts have recently issued updated ratings on Aclaris Therapeutics, Inc. (ACRS) stock. Of the recent 64 rating actions, 8 were upgrades and 7 were downgrades. 16 analysts currently cover ACRS.
Analyst Recommendation Trends
ACRS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$6M
↓ 17.2% YoY
Revenue Next Year
$6M
↑ 2.3% YoY
EPS This Year
$-0.67
EPS Next Year
$-0.76
↑ 14.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast ACRS EPS of $-0.67 for the current fiscal year, based on estimates from 8 analysts. The ACRS revenue forecast is $6M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ACRS stock forecast is supported by two independent data sources: analyst consensus ratings from 16 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ACRS price target is $10.60 (+143.1% upside), with an analyst consensus of Buy.
The ACRS short-term stock prediction for tomorrow is $4.28 (-1.78%).
Aclaris Therapeutics, Inc. trades on NASDAQ under the ticker ACRS. The ACRS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 81% of covering analysts.
Frequently asked questions
ACRS forecast · 8 questionsAccording to 16 Wall Street analysts, the average 12-month ACRS price target is $10.60, with a high forecast of $12.00 and a low of $10.00. The median price target is shown in the chart above when available. This implies +143.1% potential upside from the current price of $4.36.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.